{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:14:50Z","timestamp":1789150490602,"version":"build-2803163510"},"reference-count":44,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Blockage of PD-1 with drugs such as nivolumab (Nivo) and pembrolizumab (Pembro) has been successfully implemented in the treatment of Hodgkin lymphoma among other types of tumors. Exorbitant costs hinder access for many patients living in low- and middle-income countries (LMICs). Dose reductions on the basis of pharmacodynamic studies have been used to allow access to these drugs to patients with no further options because of economic constraints. In this study, we aimed to systematically review and assess evidence regarding the efficacy and safety of this adapted intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>An expert librarian designed and conducted a literature search in MEDLINE, Scopus, Web of Science, EMBASE, Cochrane Central, and clinicaltrials.gov. Screening was conducted in a title\/abstract and full-text phase independently and in duplicate. Primary outcomes were overall survival, overall response rates (ORRs), and incidence of adverse events (AEs). Data extraction was performed independently and in duplicate as well. A qualitative synthesis was performed and reported in the results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Six studies investigated Nivo as an intervention, two Pembro, and 1 both therapies, with a total of 161 patients overall. One study had a single-arm prospective trial design and the rest a retrospective cohort design. ORR ranged from 66% to 100%, with complete response rates between 38% and 75%. The incidence of AEs was mostly high across all studies ranging from 27% to 93%, most of it composed of grade 1-2 AEs (27%-80%). No study reported health-related quality-of-life outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Low-dose anti-PD1 immune checkpoint inhibitors have shown to be adequate candidates for testing of their efficacy in randomized trials and could improve access to these high-cost medications for patients with Hodgkin lymphoma both in LMICs and high-income countries.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-24-00538","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:45:36Z","timestamp":1757353536000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":5,"title":["Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed\/Refractory Hodgkin Lymphoma: A Systematic Review"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-9130","authenticated-orcid":true,"given":"H\u00e9ctor A.","family":"Vaquera-Alfaro","sequence":"first","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"},{"name":"Centro de An\u00e1lisis Avanzado de Informaci\u00f3n Cient\u00edfica 360, Facultad de Medicina, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"},{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-6856","authenticated-orcid":true,"given":"Jos\u00e9 Emiliano","family":"Montelongo-Cepeda","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"},{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0443-2191","authenticated-orcid":true,"given":"Antonio","family":"Vega-Mateos","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4805-6809","authenticated-orcid":true,"given":"Anah\u00ed","family":"Morales-Pedraza","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2300-7075","authenticated-orcid":true,"given":"Hayde\u00e9","family":"Verduzco-Aguirre","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen's University, Kingston, Canada"},{"name":"Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute, Kingston, Canada"},{"name":"Department of Hemato-Oncology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-6427","authenticated-orcid":true,"given":"David","family":"G\u00f3mez Almaguer","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-7913","authenticated-orcid":true,"given":"Luis","family":"Villela","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Universidad Aut\u00f3noma de Sinaloa, Campus Culiac\u00e1n, Culiac\u00e1n, M\u00e9xico"},{"name":"Hospital Fernando Ocaranza, ISSSTE and Centro Medico Dr Ignacio Chavez, ISSSTESON, Hermosillo, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-439X","authenticated-orcid":true,"given":"Perla R.","family":"Colunga-Pedraza","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888"},{"key":"e_1_3_7_5_2","unstructured":"Truven Health Analytics: Micromedex RED BOOK [database on the Internet]. Greenwood Village CO IBM Watson Health 2024 [cited 2024 Oct 4]. https:\/\/www.micromedexsolutions.com"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0177-2"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02029-1"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_3_7_10_2","unstructured":"Wells GA Shea B O'Connell D et al: The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa ON Ottawa Hospital Research Institute 2014 [cited 2024 Oct 4]. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.18620\/ctt-1866-8836-2018-7-2-28-35"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000480"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-02085-6"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153267"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847188.87255.f7"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188171"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000411"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2931-z"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.2020014"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2787"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04077-4"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.02.009"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00290-4"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010334"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33534"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030682"},{"key":"e_1_3_7_29_2","article-title":"Low-dose anti-PD(L)1 for the treatment of solid malignancies","author":"Souza IAdA","unstructured":"Souza IAdA, Dobbert BdM, Sao Jose BG, et al: Low-dose anti-PD(L)1 for the treatment of solid malignancies. JCO Glob Oncol 10.1200\/GO.24.00122","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01015"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.013"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00072-X"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2024.20.10_suppl.112"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02347"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00131"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.875"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32852"},{"key":"e_1_3_7_38_2","article-title":"Challenge of incorporating new drugs for breast cancer in Brazil: A proposed framework for improving access to innovative therapies","author":"Barrios C","unstructured":"Barrios C, Freitas-Junior R, Martins S, et al: Challenge of incorporating new drugs for breast cancer in Brazil: A proposed framework for improving access to innovative therapies. JCO Glob Oncol 10.1200\/GO.20.00566","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100035"},{"key":"e_1_3_7_40_2","article-title":"Cancer control in low- and middle-income countries: Is it time to consider screening?","author":"Shah SC","unstructured":"Shah SC, Kayamba V, Peek RM Jr, et al: Cancer control in low- and middle-income countries: Is it time to consider screening? JCO Glob Oncol 10.1200\/JGO.18.00200","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00700-7"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00463-0"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00460-0"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.003"},{"key":"e_1_3_7_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03971-7"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-24-00538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:45:46Z","timestamp":1757353546000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-24-00538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1200\/GO-24-00538"],"URL":"https:\/\/doi.org\/10.1200\/go-24-00538","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400538"}}